Non-muscle Invasive Bladder Cancer
Conditions
Interventions
Treatment arm: Administration of oral UFT 400mg/day for 2 years
Control arm: No treatment
Sponsors
University of Tokyo, Department of Urology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Pathologically-proven non-muscle invasive bladder cancer after TUR-Bt with diagnosis of UC, Ta or T1, G1 or G2. Only primary cases are eligible. 2)Treated with immediate instillation of THP (20mg in 20ml saline) after TUR-Bt 3)20-79 year old 4)ECOG Performance Status of 0 or 1 5)Tolerable to oral UFT 6)Life expectancy of > 3 years 7)Reserved organ function 8)Patients who can start protocol therapy within 4 weeks after TUR-Bt 9)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Recurrent cancer 2)UC in prostatic urethra 3)History of previous therapy with UFT or systemic chemotherapy or pelvic radiotherapy 4)Serious comorbidity 5)Contraindication for UFT 6)Women who is pregnant or possibly pregnant 7)Any contraindication investigator specify
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year recurrence-free survival | — |
Countries
Japan
Contacts
Public ContactYutaka Enomoto
University of Tokyo Department of Urology
Outcome results
None listed